Yes, Cosentyx treats specific types of arthritis
Cosentyx (secukinumab) is FDA-approved for active psoriatic arthritis (PsA) in adults and children aged 2 and older, and active ankylosing spondylitis (AS, also called radiographic axial spondyloarthritis) in adults and children aged 2 and older.[1] It targets interleukin-17A (IL-17A) to reduce inflammation in these immune-mediated conditions.
How does Cosentyx work for arthritis?
It blocks IL-17A, a cytokine driving joint inflammation, pain, and damage in PsA and AS. Clinical trials showed it reduces signs and symptoms, inhibits radiographic progression in PsA, and improves spinal symptoms in AS.[1][2]
What arthritis types does it treat—and what doesn't it cover?
Approved for:
- Psoriatic arthritis (PsA): Joint inflammation linked to psoriasis.
- Ankylosing spondylitis (AS): Primarily spine inflammation.
Not approved for rheumatoid arthritis (RA), osteoarthritis (OA), or juvenile idiopathic arthritis (JIA) outside specified uses. Off-label use occurs but lacks broad regulatory backing.[1]
How does Cosentyx compare to other arthritis drugs?
| Drug | Target | Arthritis Types | Dosing |
|------|--------|-----------------|--------|
| Cosentyx (secukinumab) | IL-17A | PsA, AS | Subcutaneous injection, weekly then monthly |
| Humira (adalimumab) | TNF-alpha | RA, PsA, AS, JIA | Every other week injection |
| Enbrel (etanercept) | TNF-alpha | RA, PsA, AS | Weekly injection |
| Rinvoq (upadacitinib) | JAK inhibitor | RA, PsA, AS | Daily oral |
Cosentyx often works after TNF inhibitors fail; head-to-head trials show similar efficacy to adalimumab in AS but better skin clearance in PsA.[2][3]
Common side effects and patient concerns
Upper respiratory infections (14%), diarrhea (4%), and oral herpes (3%) top the list. Serious risks include infections (e.g., TB reactivation), inflammatory bowel disease flares, and rare hypersensitivity. Patients report injection-site reactions; monitor for IBD history.[1]
When does the Cosentyx patent expire?
Key U.S. patents expire between 2026 and 2031, with formulation patents extending to 2036. Challenges from Amgen and others are ongoing; biosimilars could enter post-2030 if litigation favors generics. Check DrugPatentWatch.com for updates.[4]
[1]: Cosentyx Prescribing Information, Novartis, FDA.gov
[2]: Mease PJ et al., Lancet (2014) – FUTURE 2 PsA trial
[3]: Baeten D et al., Ann Rheum Dis (2015) – AS head-to-head
[4]: DrugPatentWatch.com – Secukinumab patents